.svg)
Better Robotics. Better Implants. Better Knee Replacements.
Our investment window for this raise is now closed. We want to thank you for your interest and support throughout this process. Investors who share our passion for innovation and a patient-first approach to joint surgery are what keep us moving. Stay tuned for more updates on our progress as we look forward to our planned Nasdaq listing and beyond.
Share Price
How Dr. Doug Unis and Benjamin Sexson Built Monogram
Dr. Doug Unis wasn’t surprised 100,000 knee replacements were failing every year. Surgeons relied on hand saws, jigs, metal hammers, and even eyeball measurements. He realized robotics could be the solution, so he got an NIH grant to buy one. But something was missing.
Ben ran the R&D team at the company that supplied the robotic cutting tools Doug needed and immediately saw the potential in Doug’s plan, so he joined Monogram to help lead the business side of things. Ben was experienced in the industry and brought the marketing know-how to help grow Monogram’s business.
Watch our LIVE Demo
We put our robotic technology to the test. Watch Dr. Doug Unis perform a LIVE knee replacement on a cadaver by controlling our robot from over 2,000 miles away.
Precision Robotics 🤝 Personalized Implants
Our system will marry custom, 3D-printed implants tailored to each patient’s anatomy with the robotic precision needed to install them. Thanks to our technology, our patients will have a more stable, better-fitting knee replacement with fewer incisions.
Sign Up For Company Updates
The First Surgical Robot of Its Kind
Surgery is an incredibly invasive stressful process. Our surgical robots precisely create a digital map of a patient and make as minimal incisions as possible alongside surgeons to create a better surgery experience.
In fact, this year we held a live demonstration where a Monogram robot successfully operated on a cadaver alongside a surgeon in front of a virtual audience of over 5,000 people.
What makes the Monogram robot so effective?
- 7 degrees of freedom to boost range of motion
- Closed loop tracking
- Active navigated milling gently clears space for the implant
The World Deserves Personalized Implants
Patients have been forced to compromise with poorly fitting implants for decades. We fixed it. Our 3D-printed implants are customized to match each patient’s anatomy as closely as possible. The result is a decrease in micro-mobility which increases the likelihood of acceptance of the implant by a patient.
50% of Knee Replacements Will Be Robotic by 2027
By 2027, 50% of all knee replacements will be robotic, up from just 12% today. We hope to capture a fraction of this massive $19.4B market by having the first active navigated robotic arm.
NASDAQ Here We Come. Meet MGRM.
This is an especially exciting time in our journey as we plan to list on the Nasdaq. Once we’re on the exchange our shares will be eligible to be bought by ETFs, mutual funds, institutional investors, and be covered by investment banks. And this is an opportunity for investors to own shares in a company before it’s planned to trade on an exchange.
Sign Up For Company Updates
Our Business Model
Our robotic system is a one-time sale that will create a continuous revenue stream. Once a hospital or clinic buys our robotic system, they’ll need to buy implants, cutting tools, and licensing & service subscriptions from us. We expect to start making sales in 2024 pending FDA approval.
Press
March 28, 2023
Monogram Orthopaedics Inc. is pleased to announce the completion of its first pre-submission meeting with the U.S. Food and Drug Administration
Monogram Orthopaedics Inc. is pleased to announce the completion of its first pre-submission meeting with the U.S. Food and Drug Administration
March 23, 2023
Monogram Makes Orthopedic History! Fully Remote Robotic Surgical Demo
March 23, 2023
Monogram Investor Webinar w/Q&A
What People are Saying
.png){kind=logo}
"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."
.jpeg){kind=logo}
"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."
"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".
"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."
"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."
Meet the Team
Douglas Unis, Md
Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.
Benjamin Sexson - CEO
Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.
Noel Knape
Mr. Knape has over 25 years of experience leading financial departments in multinational, publicly-traded companies. He holds a Master of International Management from the American Graduate School of International Management.
Kamran Shamaei, PhD
Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.
Christopher Scifert, PhD
Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.
Kevin Posey
Muhammad Afnan
Sophia Sangiorgio, PhD
Laura Gilmour
Matt DiCicco, M.S.
Dr. Roshan Shah
Robert Jamieson
Dr. Matthew E. Heinrich
Darwin Chen
Dr. Gregory Catlett
FAQs
PUBLIC OFFERING AND LISTING
Please note that SEC Rule 144 mandates that shares purchased under Reg CF (Regulation Crowdfunding) are not eligible for immediate trading and have a 12-month required lock-up period starting from when the investment closed. Equity Stock Transfer has records of when any Reg-CF series-C investments closed.
TRANSFER AGENT
- If you have already paid and registered for Online Access to our shareholder portal, and created your username and password, please skip to step 4.
- To transfer your free trading shares to your broker, you must obtain Online Access here: https://monogram-orthopaedics.equitystock.com/pay and follow the directions. Your DRS (Direct Registration System) transfer agent fees to transfer your shares to your broker are covered when you obtain Online Access.
- After you complete the payment for Online Access, you will receive email instructions on how to register.
- Once you have registered and created your username and password, through the Online Access portal, you will be able to download your Common Stock book-entry statement along with a Welcome Letter on how to initiate the DRS process through your broker.
- Once your broker initiates the DRS process, we will be able to transfer the shares to your brokerage account.
PRIOR INVESTMENTS
GENERAL
FOR FURTHER INFORMATION
This page may include ''forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page. Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
DealMaker Securities, LLC is being compensated a 4% commission from the lead Selling Agent engaged by Monogram Orthopaedics Inc. in regards to advertising of this investment. The Company has engaged Digital Offering, LLC (“Digital Offering”) to act as lead selling agent (which we sometimes refer to as the “Selling Agent”) to offer the shares of our common stock, par value $0.001 (the “Common Stock”) to prospective investors in this offering on a “best efforts” basis, which means that there is no guarantee that any minimum amount will be received by the Company in this offering. The Company will pay a cash commission of 7.00% to Digital Offering on sales of the shares of Common Stock. See “Plan of Distribution” in the Offering Circular for details of compensation payable to the Selling Agent in connection with the offering. DealMaker Securities, LLC is not affiliated with other companies mentioned herein.
*NASDAQ Ticker Reservation Tracking #ME9437IN. Our request to reserve the ticker symbol "MGRM" for Monogram Orthopaedics Inc has been approved and will be reserved until 20 September 2024.
Join the Discussion